基于SuFEx的抗结核化合物不可逆地抑制Pks13
Inna V Krieger1, Paridhi Sukheja2, Baiyuan Yang2
1Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA.
Nature
|July 31, 2025
概括
一种新型化合物CMX410向Pks13,这是Mycobacterium tuberculosis (Mtb) 细胞壁生物合成中的一个必不可少的酶. 这种候选药物对抗药物耐药的Mtb菌株具有有效性,并且具有良好的安全性.
科学领域:
- 医学化学
- 微生物学
- 药物发现
背景情况:
- 结核病是由Mycobacterium tuberculosis (Mtb) 引起的,是全球主要的一种传染病.
- 现有的结核病治疗需要长时间,并面临多抗药性 (MDR) 和广泛抗药性 (XDR) 菌株的挑战.
- 迫切需要针对关键MTB途径的新疗法来缩短治疗时间和克服耐药性.
研究的目的:
- 引入CMX410,一种针对Pks13的新型临床前共价化合物.
- 评估CMX410对Mtb的疗效和作用机制.
- 评估CMX410的安全性和药理特性.
主要方法:
- CMX410被设计为一种酸 (SuFEx) 协同抑制剂.
- 该化合物的活性在体外对药物敏感和耐药的Mtb菌株进行了测试.
- 在Mtb感染的小鼠模型中评估了疗效.
- 抑制机制涉及向Pks13乙烯转移酶域.
- 评估了药理和安全性,包括对大鼠的毒性研究.
主要成果:
- CMX410对药物敏感和药物耐药的Mtb菌株表现出同样强的活性.
- 该化合物在多种小鼠Mtb感染模型中有效.
- CMX410通过在乙烯转移酶域中与催化血清形成β- 乳酸酶,从而不可逆地抑制Pks13.
- CMX410具有很高的标选择性和优秀的药理学和安全性,在高剂量的老鼠中没有不良影响.
- 在药物组合测试中,CMX410表现良好.
结论:
- CMX410代表了一类有前途的结核治疗药物候选者.
- 它独特的作用机制和有利的特征为目前的细胞壁生物合成抑制剂提供了潜在的替代品.
- CMX410的功效,安全性和口服生物可用性支持其在结核病药物开发中的进步.
更多相关视频
09:57System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
8.7K
09:08From a Natural Product to Its Biosynthetic Gene Cluster: A Demonstration Using Polyketomycin from Streptomyces diastatochromogenes Tü6028
Published on: January 13, 2017
17.3K
相关概念视频
01:27Combined Effects of Drugs: Synergism
4.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.8K
01:28Pulmonary Tuberculosis V
239
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
239
01:45Destabilization of Microtubules
2.8K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.8K